Ulcerative colitis is a form of inflammatory bowel disease that affects the large intestine, or colon. The main symptom of ulcerative colitis is diarrhea, often with blood in the stool. Other symptoms may include abdominal pain, weight loss, and fatigue.
Ulcerative colitis is thought to be caused by a combination of genetic and environmental factors. The exact cause is unknown. Treatment typically involves medication to reduce inflammation and symptoms. Surgery may be necessary in some cases.
Asacol is a drug used to treat mild to moderate active Crohn's disease and ulcerative colitis. It is a 5-aminosalicylic acid (5-ASA) drug. 5-ASA drugs are anti-inflammatory drugs used to treat inflammatory bowel diseases (IBD).
Asacol is taken by mouth. It is available as a delayed-release tablet, an extended-release tablet, and a delayed-release mesalamine enema. The delayed-release tablet is taken two or three times a day. The extended-release tablet is taken once a day. The enema is given once a day.
There are several reasons why Asacol may have lost its market share, including the introduction of generic versions of the drug and the availability of other IBD treatments.
Asacol was first approved by the FDA in 1996. The medication was a5-aminosalicylic acid (5-ASA) drug, which is used to treat ulcerative colitis and Crohn's disease. 5-ASA drugs work by reducing inflammation in the gastrointestinal tract. Asacol was available as a delayed-release tablet, which allowed it to be released slowly into the intestine over a period of time.
In 2012, the FDA approved the first generic version of Asacol. The availability of a generic version of the drug likely led to a decline in sales of Asacol. In addition, there are other 5-ASA drugs available that may be just as effective as Asacol. These drugs include Mesalamine and Sulfasalazine.
It's also possible that the discontinuation of Asacol was due to the availability of other IBD treatments. Learn more on Why was Asacol Discontinued